Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 8/20 | 0.35 |
| ▸ | GRM3 | Q14832 | 8/20 | 0.35 |
| ▸ | GRM8 | O00222 | 1/20 | 0.35 |
| ▸ | GRM6 | O15303 | 1/20 | 0.35 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7392780 | 0.76 | GRM2 (0.46) | GRM2GRM3 | |
| SCHEMBL5092142 | 0.76 | GRM2 (0.55) | GRM2GRM3GRM8GRM6GRM7 | |
| SCHEMBL5093944 | 0.75 | GRM2 (0.55) | GRM2GRM3 | |
| SCHEMBL5089416 | 0.73 | GRM2 (0.56) | GRM2GRM3 | |
| SCHEMBL232413 | 0.72 | GRM2 (0.48) | SMN1; SMN2KDM4EALDH1A1L3MBTL1GRM2 | |
| SCHEMBL7390481 | 0.71 | GRM2 (0.38) | GRM2GRM3 | |
| SCHEMBL7385604 | 0.69 | CYP1A2 (0.40) | ALDH1A1L3MBTL1 | |
| SCHEMBL233634 | 0.64 | GRM2 (0.47) | GRM2GRM3 | |
| SCHEMBL5100253 | 0.64 | GRM2 (0.52) | GRM2GRM3 | |
| SCHEMBL20309426 | 0.64 | SMN1; SMN2 (0.48) | SLC6A3SMN1; SMN2KDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142388-A1 | 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-29 | — | — | US | claimed |
| US-7381746-B2 | 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-03 | — | — | US | disclosed |
| US-20060142388-A1 | 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142388-A1 | 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative | GRIA3, GRIN3A, GRM3 | SLC6A3 56/4885SMN1; SMN2 1475/4885KDM4E 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.